Sightful Invest
  • Business
  • Investing
  • Politics
  • Stock
Top Posts
Comey to be arraigned in federal court after...
Comey pleads not guilty in court after indictment...
Houthi rebels test US ceasefire with deadly strike...
Kushner joins Witkoff for Gaza ceasefire talks as...
Cuomo rips Mamdani’s freebie ‘fantasy,’ says AOC proved...
White House escalates shutdown consequences as Democrats show...
Moderate Dem undercuts Jeffries on ObamaCare compromise as...
MIKE DAVIS: The Supreme Court betrayed again —...
Senate Democrats defy White House warnings, again block...
Greta Thunberg slammed for using image of starved...
  • Business
  • Investing
  • Politics
  • Stock

Sightful Invest

Politics

HHS slams ‘under-tested’ mRNA technology as Trump cuts Moderna’s vaccine funding

by admin May 29, 2025
May 29, 2025
HHS slams ‘under-tested’ mRNA technology as Trump cuts Moderna’s vaccine funding

President Donald Trump’s Department of Health and Human Services (HHS) is terminating awards totaling more than $750 million dollars that were provided to pharmaceutical manufacturer Moderna to help facilitate its production of mRNA-based bird flu vaccines. 

During President Joe Biden’s final week in office, his administration awarded $590 million to Moderna to help speed up its production of mRNA-based vaccines. The $590 million award followed a separate $176 million award Biden gave to Moderna earlier last year for mRNA vaccine technology.

Messenger RNA vaccines are a newer type of vaccine technology, which was utilized by companies like Moderna and Pfizer to develop their COVID-19 vaccines. The vaccine technology was at the center of a lot of criticism amid the coronavirus pandemic for potentially being associated with adverse side effects in some people who took them, such as myocarditis.

Trump administration officials previously hinted at the potential that this funding could be terminated, citing a lack of oversight during the Biden administration pertaining to vaccine production. 

‘After a rigorous review, we concluded that continued investment in Moderna’s H5N1 mRNA vaccine was not scientifically or ethically justifiable,’ HHS Communications Director Andrew Nixon said. ‘This is not simply about efficacy — it’s about safety, integrity, and trust. The reality is that mRNA technology remains under-tested, and we are not going to spend taxpayer dollars repeating the mistakes of the last administration, which concealed legitimate safety concerns from the public.’

The announcement reflects a larger shift in federal vaccine priorities, after HHS Secretary Robert F. Kennedy Jr. announced earlier this week that COVID-19 vaccines would be removed from the federal government’s list of recommended vaccines for children and pregnant women. 

Meanwhile, a report from Senate Republicans released earlier this month suggested the Biden administration withheld critical safety data and downplayed known risks tied to the mRNA COVID-19 vaccine. In particular, the Senate report focuses on HHS’ awareness of, and response to, cases of myocarditis — a type of heart inflammation — following COVID-19 vaccination.

‘Rather than provide the public and health care providers with immediate and transparent information regarding the risk of myocarditis following mRNA COVID-19 vaccination, the Biden administration waited until late June 2021 to announce changes to the labels for the Moderna and Pfizer COVID-19 vaccines based on the ‘suggested increased risks’ of myocarditis and pericarditis,’ the Senate report states. ‘Even though CDC and FDA officials were well aware of the risk of myocarditis following COVID-19 vaccination, the Biden administration opted to withhold issuing a formal warning to the public for months about the safety concerns, jeopardizing the health of young Americans.’

In response to the Trump administration’s funding termination, Moderna put out a press release acknowledging the move, but also touting the ‘safety profile’ observed amid its work on a new mRNA bird flu vaccine.

‘While the termination of funding from HHS adds uncertainty, we are pleased by the robust immune response and safety profile observed in this interim analysis of the Phase 1/2 study of our H5 avian flu vaccine and we will explore alternative paths forward for the program,’ said Stéphane Bancel, Chief Executive Officer of Moderna. ‘These clinical data in pandemic influenza underscore the critical role mRNA technology has played as a countermeasure to emerging health threats.’

Fox News Digital’s Brooke Singman contributed to this report.

This post appeared first on FOX NEWS

previous post
State Department says it will ‘aggressively’ revoke visas for Chinese students
next post
Amazon taps Xbox co-founder to lead new team developing ‘breakthrough’ consumer products

You may also like

‘I’ve never seen this’: Top Republican details level of Secret...

September 19, 2024

Senate GOP pushes Trump budget framework through after...

April 5, 2025

White House responds to ‘Rocket Man’ and North...

July 31, 2025

Grassley releases new details of Iran-backed assassination plots...

September 6, 2024

Vulnerable House Dem dodges question on VP Harris’...

July 24, 2024

Trump’s surgeon general pick touted as ‘fierce’ MAHA...

May 2, 2025

Morning Glory: The worst debate in the history...

September 12, 2024

Trump brings back Diet Coke button to White...

January 21, 2025

Morning Glory: Kamala Harris is not ready to...

August 13, 2024

Judge restricts DOGE access to federal databases, finding...

June 10, 2025

Recent Posts

  • Comey to be arraigned in federal court after being indicted for alleged false statements, obstruction
  • Comey pleads not guilty in court after indictment on alleged false statements, obstruction
  • Houthi rebels test US ceasefire with deadly strike on cargo ship
  • Kushner joins Witkoff for Gaza ceasefire talks as Trump pushes peace plan: ‘Cautiously optimistic’
  • Cuomo rips Mamdani’s freebie ‘fantasy,’ says AOC proved socialism fails after killing NYC Amazon deal

    Sign up for our newsletter to receive the latest insights, updates, and exclusive content straight to your inbox! Whether it's industry news, expert advice, or inspiring stories, we bring you valuable information that you won't find anywhere else. Stay connected with us!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (936)
    • Investing (3,147)
    • Politics (3,845)
    • Stock (4)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: sightfulinvest.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 Sightful Invest. All Rights Reserved.